Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 10;7:1689. doi: 10.1038/s41598-017-01584-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The integration of human-based in vitro test models into a down-scaling process of common practice is often neglected. One major flaw is a low correlation of in vitro tests to in vivo studies. In this study we propose a procedure to overcome this hurdle. In a large-scale in vitro screening approach, we identified an accurate and suitable condition for biomaterial testing and proved its validity by correlation to a well-described effect-the fibrotic progression - observed in vivo. On basis of this screening approach a well-defined in vitro test setting with a high predictive power was composed of (I) plasma pretreatment of biomaterials’ surface and (II) a set of highly predictive readout factors. We hope that the obtained data justifies a down-scaling of the in vitro test procedure to the identified condition and will be applied for large-scale biomaterial candidate screenings in following studies. Finally, followed by current common practice to study promising candidates in systemic animal models, and carrying the positively-proofed biomaterials in human subjects.